

Pioneering Cellular Therapeutics to Reverse Aging and Eliminate Cancer

TREATING DISEASES OF AGING AND TREATING AGING AS DISEASETM

- Immorta Bio is revolutionizing longevity cellular medicine
- Our proprietary therapeutics kill senescent (old) cells and introduce young cells
- We leverage patient-derived rejuvenated stem cells and enhanced immune cells
- We restore the body's innate ability to combat cancers and age-related diseases

MARKET OPPORTUNITY

Rapid Growth: Longevity and senolytics market projected to reach \$46B by 2033

KEYS TO SUCCESS

- Proven Team of biotech leaders and eminent scientists; 9 team members hold MDs/PhDs
- Two Therapeutic Platforms, AI enabled R&D, strong IP Portfolio: 23 patents
- Clinical Momentum: Entering the clinical stage with three IND's to be cleared in 2025/2026
- Clear Exit: IPO planned in two years


ROAD TO IPO

- Clinical Trials: Complete Phase I/IIa longevity/lung cancer trial, launch two Phase I/IIa longevity/liver failure trials
- R&D: Advance longevity technologies and oncology franchise, expand IP, add peer-reviewed publications
- Alliances: Academic institutions, foundations and advanced biotech / pharma entities

OUR OVERALL OBJECTIVES

- Mission-Oriented: Achieve FDA approval for radical life extension therapeutics
- Shareholder-Oriented: Grow valuation to \$1B through advancing tech, IP, and clinical execution

PIPELINE



Reverse Aging - Prevent & Treat Cancer